ClinicalTrials.gg
CompletedNCT00174941FOCUSUpdated Jan 27, 2011Results posted

Long-Term Safety of Febuxostat in Subjects With Gout.

A Phase 2 interventional study of Febuxostat and Febuxostat in Gout, sponsored by Takeda. Completed. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2011-01-27.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
116
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing febuxostat in Gout — 1 open to participants now, 1 under way, none of them phase 3. Febuxostat · Gout.

Enrollment
14th of 29
116 · median 109
Started
2001
with 1 other
Phase 2
9 of 29
none open now
Registered
4th of 29
by date
Lead sponsor
11 of 29
Takeda

Among the 29 studies testing febuxostat in Gout, this one is the 14th largest by enrollment, is one of 2 that started in 2001, is one of 9 in phase 2, and was the 4th registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 29 studies testing febuxostat in Gout is open now. Recruiting first, the newest first:

About febuxostat

Febuxostat: first FDA approval 2009 (ULORIC), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing febuxostat in Gout, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety of febuxostat, once daily (QD), in maintaining serum urate levels within clinically acceptable levels in subjects with gout.

Read the detailed description

Uric acid is the end product of purine degradation in humans. Hyperuricemia, a urate concentration in serum exceeding the limit of urate solubility (approximately 7.0 milligrams per deciliter [mg/dL]), is a common biochemical abnormality. Aberrations in any of the multiple mechanisms involved in the production and/or excretion of uric acid may increase serum urate concentrations, with persistent hyperuricemia as a marker for extracellular fluid monosodium urate supersaturation. As such, hyperuricemia is a necessary (but often not sufficient) risk factor for monosodium urate crystal deposition in tissues and is the fundamental pathophysiological process underlying the clinical manifestations of gout, which is a chronic disease characterized by urate crystal formation and deposition in joints and bones. Gout may progress from episodic attacks of acute inflammatory arthritis to a disabling chronic disorder characterized by deforming arthropathy; destructive deposits of urate crystals (tophi) in bones, joints, and other organs; structural and functional renal impairment due to interstitial urate crystal deposition; and urinary tract stones composed entirely or in part of uric acid crystals. Management of gout requires chronic treatment aimed at lowering serum urate into a subsaturating range (usually \<6.0 mg/dL) in which crystal formation and deposition are prevented or reversed.

Febuxostat (TMX-67) is a non-purine selective xanthine oxidase inhibitor being developed as an orally administered agent for management of hyperuricemia in patients with gout.

Subjects who want to participate in this study will have successfully completed study TMX-00-004 (NCT00174967).

All participants will initially receive an 80 mg dose. Dose titrations will occur in order to obtain and maintain clinically acceptable serum urate levels.

03

Conditions studied

  • Gout

Browse trials for

Keywords

  • Uric acid
  • xanthine oxidase
  • tophi
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hyperuricemia (serum uric acid ≥8.0 mg/dL upon entering parent study TMX-00-004).
  • Must meet American College of Rheumatology criteria for gout.
  • Must have adequate renal function (serum creatinine \<1.5 mg/dL).
  • Must have completed four weeks of double-blind dosing in Study TMX-00-004.
  • Must not have experienced any serious study drug-related Adverse Events in Study TMX 00-004.
  • Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • History of xanthinuria
  • Alcohol consumption >14/week
  • Has a History of significant concomitant illness
  • Has active liver disease.
  • Has a greater than 50 kg/m2
  • Any other significant medical condition that would interfere with the treatment, safety or compliance with the protocol, as defined by the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    1

    Drug: Febuxostat

  • Experimental
    2

    Drug: Febuxostat

  • Experimental
    3

    Drug: Febuxostat

Interventions

  • Febuxostat 40 mg, tablets, orally, once daily, based on serum urate level.

    Also known as: TMX-67, Tei-6720, Uloric

  • Febuxostat 80 mg, tablets, orally, once daily, based on serum urate level.

    Also known as: TMX-67, Tei-6720, Uloric

  • Febuxostat 120 mg, tablets, orally, once daily, based on serum urate level.

    Also known as: TMX-67, Tei-6720, Uloric

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 6 Visit.

    Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 6 visit was summarized.

    Time frame: Month 6

  2. Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 12 Visit.

    Serum urate values were obtained at the Month 12 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 12 visit was summarized.

    Time frame: Month 12

  3. Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 18 Visit.

    Serum urate values were obtained at the Month 18 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 18 visit was summarized.

    Time frame: Month 18

  4. Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 24 Visit.

    Serum urate values were obtained at the Month 24 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 24 visit was summarized.

    Time frame: Month 24

  5. Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 36 Visit.

    Serum urate values were obtained at the Month 36 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 36 visit was summarized.

    Time frame: Month 36

  6. Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 48 Visit.

    Serum urate values were obtained at the Month 48 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 48 visit was summarized.

    Time frame: Month 48

  7. Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 60 Visit.

    Serum urate values were obtained at the Month 60 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 60 visit was summarized.

    Time frame: Month 60

  8. Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Final Visit.

    The percentage of subjects whose serum urate was \<6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected.

    Time frame: Last Visit on treatment (up to 66 months).

Secondary outcomes

  1. Percent Change in Serum Urate Levels From Baseline at Month 6 Visit.

    Serum urate values were obtained at the Month 6 visit. The percent change in serum urate from baseline to the Month 6 visit was summarized.

    Time frame: Baseline and Month 6

  2. Percent Change in Serum Urate Levels From Baseline at Month 12 Visit.

    Serum urate values were obtained at the Month 12 visit. The percent change in serum urate from baseline to the Month 12 visit was summarized.

    Time frame: Baseline and Month 12

  3. Percent Change in Serum Urate Levels From Baseline at Month 18 Visit.

    Serum urate values were obtained at the Month 18 visit. The percent change in serum urate from baseline to the Month 18 visit was summarized.

    Time frame: Baseline and Month 18

  4. Percent Change in Serum Urate Levels From Baseline at Month 24 Visit.

    Serum urate values were obtained at the Month 24 visit. The percent change in serum urate from baseline to the Month 24 visit was summarized.

    Time frame: Baseline and Month 24

  5. Percent Change in Serum Urate Levels From Baseline at Month 36 Visit.

    Serum urate values were obtained at the Month 36 visit. The percent change in serum urate from baseline to the Month 36 visit was summarized.

    Time frame: Baseline and Month 36

  6. Percent Change in Serum Urate Levels From Baseline at Month 48 Visit.

    Serum urate values were obtained at the Month 48 visit. The percent change in serum urate from baseline to the Month 48 visit was summarized.

    Time frame: Baseline and Month 48

  7. Percent Change in Serum Urate Levels From Baseline at Month 60 Visit.

    The secondary outcome was the mean percent change from baseline to Month 60 visit as assessed by serum urate levels collected at baseline and at the Month 60 visit by dose at observation.

    Time frame: Baseline and Month 60

  8. Percent Change in Serum Urate Levels From Baseline at Final Visit.

    The percent change in serum urate from baseline to the final visit was summarized. The final visit was the last visit at which a serum urate value was collected.

    Time frame: Baseline and Last Visit on treatment (up to 66 months).

07

Results

Posted Jul 16, 2009

Participant flow

Subjects were enrolled at 23 investigational sites in the United States from 21 March 2001 to 29 December 2006

Participant flow — Overall Study
MilestoneFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal Febuxostat
Started87929116
Completed6411158
Not completed2381858
Withdrew: Adverse event110213
Withdrew: Protocol violation0101
Withdrew: Lost to follow-up0325
Withdrew: Personal reason(s)014822
Withdrew: Gout flare0448
Withdrew: Reason not specified1629

Outcome measures

PrimaryPercentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 6 Visit.

Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 6 visit was summarized.

Time frame:
Month 6
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 6 Visit.
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal Febuxostat
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 6 Visit.50936582
SecondaryPercent Change in Serum Urate Levels From Baseline at Month 6 Visit.

Serum urate values were obtained at the Month 6 visit. The percent change in serum urate from baseline to the Month 6 visit was summarized.

Time frame:
Baseline and Month 6
Reported as:
Mean · percent change from baseline
Percent Change in Serum Urate Levels From Baseline at Month 6 Visit.
percent change from baselineFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal Febuxostat
Percent Change in Serum Urate Levels From Baseline at Month 6 Visit.-35.9 ± 9.55-50.6 ± 9.84-47.6 ± 19.6-48.3 ± 13.07
PrimaryPercentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 12 Visit.

Serum urate values were obtained at the Month 12 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 12 visit was summarized.

Time frame:
Month 12
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 12 Visit.
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal Febuxostat
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 12 Visit.57856779
PrimaryPercentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 18 Visit.

Serum urate values were obtained at the Month 18 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 18 visit was summarized.

Time frame:
Month 18
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 18 Visit.
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal Febuxostat
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 18 Visit.50825774
PrimaryPercentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 24 Visit.

Serum urate values were obtained at the Month 24 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 24 visit was summarized.

Time frame:
Month 24
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 24 Visit.
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal Febuxostat
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 24 Visit.63769277
PrimaryPercentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 36 Visit.

Serum urate values were obtained at the Month 36 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 36 visit was summarized.

Time frame:
Month 36
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 36 Visit.
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal Febuxostat
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 36 Visit.67849284
PrimaryPercentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 48 Visit.

Serum urate values were obtained at the Month 48 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 48 visit was summarized.

Time frame:
Month 48
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 48 Visit.
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal Febuxostat
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 48 Visit.83928590
PrimaryPercentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 60 Visit.

Serum urate values were obtained at the Month 60 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 60 visit was summarized.

Time frame:
Month 60
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 60 Visit.
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal Febuxostat
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 60 Visit.100939193
PrimaryPercentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Final Visit.

The percentage of subjects whose serum urate was \<6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected.

Time frame:
Last Visit on treatment (up to 66 months).
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Final Visit.
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal Febuxostat
Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Final Visit.100828183
SecondaryPercent Change in Serum Urate Levels From Baseline at Month 12 Visit.

Serum urate values were obtained at the Month 12 visit. The percent change in serum urate from baseline to the Month 12 visit was summarized.

Time frame:
Baseline and Month 12
Reported as:
Mean · percentage of subjects
Percent Change in Serum Urate Levels From Baseline at Month 12 Visit.
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal Febuxostat
Percent Change in Serum Urate Levels From Baseline at Month 12 Visit.-35.0 ± 13.16-49.7 ± 9.26-49.3 ± 15.77-48.3 ± 11.94
SecondaryPercent Change in Serum Urate Levels From Baseline at Month 18 Visit.

Serum urate values were obtained at the Month 18 visit. The percent change in serum urate from baseline to the Month 18 visit was summarized.

Time frame:
Baseline and Month 18
Reported as:
Mean · percent change from baseline
Percent Change in Serum Urate Levels From Baseline at Month 18 Visit.
percent change from baselineFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal Febuxostat
Percent Change in Serum Urate Levels From Baseline at Month 18 Visit.-35.5 ± 16.35-48.7 ± 11.12-39.5 ± 19.36-45.4 ± 14.35
SecondaryPercent Change in Serum Urate Levels From Baseline at Month 24 Visit.

Serum urate values were obtained at the Month 24 visit. The percent change in serum urate from baseline to the Month 24 visit was summarized.

Time frame:
Baseline and Month 24
Reported as:
Mean · percent change from baseline
Percent Change in Serum Urate Levels From Baseline at Month 24 Visit.
percent change from baselineFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal Febuxostat
Percent Change in Serum Urate Levels From Baseline at Month 24 Visit.-38.9 ± 19.41-46.7 ± 11.59-54.7 ± 12.02-47.3 ± 13.24
SecondaryPercent Change in Serum Urate Levels From Baseline at Month 36 Visit.

Serum urate values were obtained at the Month 36 visit. The percent change in serum urate from baseline to the Month 36 visit was summarized.

Time frame:
Baseline and Month 36
Reported as:
Mean · percent change from baseline
Percent Change in Serum Urate Levels From Baseline at Month 36 Visit.
percent change from baselineFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal Febuxostat
Percent Change in Serum Urate Levels From Baseline at Month 36 Visit.-43.0 ± 9.14-46.9 ± 13.35-56.4 ± 13.76-48.4 ± 13.6
SecondaryPercent Change in Serum Urate Levels From Baseline at Month 48 Visit.

Serum urate values were obtained at the Month 48 visit. The percent change in serum urate from baseline to the Month 48 visit was summarized.

Time frame:
Baseline and Month 48
Reported as:
Mean · percent change from baseline
Percent Change in Serum Urate Levels From Baseline at Month 48 Visit.
percent change from baselineFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal Febuxostat
Percent Change in Serum Urate Levels From Baseline at Month 48 Visit.-50.0 ± 4.16-50.3 ± 10.61-53.8 ± 16.41-51.1 ± 11.64
SecondaryPercent Change in Serum Urate Levels From Baseline at Month 60 Visit.

The secondary outcome was the mean percent change from baseline to Month 60 visit as assessed by serum urate levels collected at baseline and at the Month 60 visit by dose at observation.

Time frame:
Baseline and Month 60
Reported as:
Mean · percent change from baseline
Percent Change in Serum Urate Levels From Baseline at Month 60 Visit.
percent change from baselineFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal Febuxostat
Percent Change in Serum Urate Levels From Baseline at Month 60 Visit.-45.5 ± 8.70-51.1 ± 13.21-59.0 ± 18.74-52.0 ± 14.32
SecondaryPercent Change in Serum Urate Levels From Baseline at Final Visit.

The percent change in serum urate from baseline to the final visit was summarized. The final visit was the last visit at which a serum urate value was collected.

Time frame:
Baseline and Last Visit on treatment (up to 66 months).
Reported as:
Mean · percent change from baseline
Percent Change in Serum Urate Levels From Baseline at Final Visit.
percent change from baselineFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal Febuxostat
Percent Change in Serum Urate Levels From Baseline at Final Visit.-49.2 ± 7.10-47.1 ± 16.42-50.7 ± 19.12-48.1 ± 16.61

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Febuxostat 40 mg QD—3/12 (25%)5/12 (41.7%)
Febuxostat 80 mg QD—14/116 (12.1%)44/116 (37.9%)
Febuxostat 120 mg QD—4/37 (10.8%)9/37 (24.3%)
Febuxostat Total—21/116 (18.1%)53/116 (45.7%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDFebuxostat Total
Intestinal Ulcers & Perforation not elsewhere classified (NEC)Gastrointestinal disorders1/120/1160/371/116
Cholecystitis and CholelithiasisHepatobiliary disorders1/121/1160/372/116
Lower Respiratory Tract and Lung InfectionsInfections and infestations1/121/1160/372/116
Spine and Neck DeformitiesMusculoskeletal and connective tissue disorders1/120/1160/371/116
Central Nervous System Hemorrhages & Cerebrovascular AccidentsNervous system disorders1/120/1160/371/116
Depressive DisordersPsychiatric disorders1/120/1160/371/116
Bladder and Urethral SymptomsRenal and urinary disorders1/120/1160/371/116
Supraventricular ArrhythmiasCardiac disorders0/125/1160/375/116
Cerebral Injuries NECInjury, poisoning and procedural complications0/120/1161/371/116
Fractures and Dislocations NECInjury, poisoning and procedural complications0/120/1161/371/116
Most frequent other events
Showing 10 of 21
Most frequent other events
EventFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDFebuxostat Total
DiarrhoeaGastrointestinal disorders0/129/1161/3710/116
Hyperlipidaemias NECMetabolism and nutrition disorders1/123/1160/374/116
Renal LithiasisRenal and urinary disorders1/122/1160/373/116
Rashes, Eruptions and ExanthemsSkin and subcutaneous tissue disorders1/122/1160/373/116
ArthropathiesMusculoskeletal and connective tissue disorders1/121/1160/372/116
Blood Amylase IncreasedInvestigations1/120/1160/371/116
Liver Function AnalysesInvestigations0/124/1162/376/116
Muscle PainsMusculoskeletal and connective tissue disorders0/120/1162/372/116
Gastrointestinal Atonic and Hypomotility Disorders NECGastrointestinal disorders0/125/1160/375/116
Headaches NECNervous system disorders0/125/1160/375/116

Baseline characteristics

Age, Customized
Age, Customized(Subjects)Febuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal
<45 years220931
45 to <65 years4401559
≥65 years219526
Age Continuous
Age Continuous(years)Febuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal
Mean54.5 ± 11.4453.9 ± 12.8551.3 ± 13.0153.3 ± 12.74
Sex: Female, Male
Sex: Female, Male(Participants)Febuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal
Female09211.0
Male87027105.0
History of Kidney Stone
History of Kidney Stone(Subjects)Febuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal
Yes011314
No86826102
Presence of Tophus
Presence of Tophus(Subjects)Febuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal
Yes1131226
No7661790
Race/Ethnicity
Race/Ethnicity(Subjects)Febuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal
Asian0022
Black or African American1539
White7712199
Hispanic0213
Other0123
Renal Function
Renal Function(Subjects)Febuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal
Normal3331248
Impaired5461768
Urine Uric Acid
Urine Uric Acid(Subjects)Febuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDTotal
Underexcretor5622188
Overproducer316726
Missing0112

2 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Colwell HH, Hunt BJ, Pasta DJ, Palo WA, Mathias SD, Joseph-Ridge N. Gout Assessment Questionnaire: Initial results of reliability, validity and responsiveness. Int J Clin Pract. 2006 Oct;60(10):1210-7. doi: 10.1111/j.1742-1241.2006.01104.x. Epub 2006 Aug 15. PubMed 16911575 ↗
  • Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009 Feb;48(2):188-94. doi: 10.1093/rheumatology/ken457. PubMed 19141576 ↗
  • Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011 Jan;17(1):7-13. doi: 10.1097/RHU.0b013e318204aab4. PubMed 21169856 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2001, a primary completion of Dec 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 15, 2005
Start
Mar 2001
Primary completionActual
Dec 2006
CompletionActual
Dec 2006
Results first posted
Jul 16, 2009
Last update
Jan 27, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00174941
Lead sponsor
Takeda
First posted
Sep 15, 2005
Start date
Mar 2001
Primary completion
Dec 2006
Completion
Dec 2006
Results posted
Jul 16, 2009
Last update
Jan 27, 2011

Study contacts

Medical Director
study chair · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Febuxostat

Start the discussion